FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1837385886> ?p ?o ?g. }

• W1837385886 endingPage "601" @default.
• W1837385886 startingPage "593" @default.
• W1837385886 abstract "BACKGROUND. Two recent chemoprevention trials demonstrated significant reductions in overall prostate cancer incidence. However, a possible increase in high-grade disease has raised concerns that the harms of the drugs, including mortality because of high-grade disease, may outweigh the benefits. The authors attempted to estimate the effect of these drugs on prostate cancer mortality to be able to better evaluate the cost-benefit tradeoff. METHODS. The authors analyzed prostate cancer incidence in the Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, which evaluated finasteride and the related compound dutasteride, respectively (both vs placebo). They used 13-year prostate cancer survival data from the Prostate, Lung, Colorectal and Ovarian (PLCO) trial to project prostate cancer mortality from incidence patterns; survival rates were applied to incident cancers according to prognostic strata, which were defined by Gleason score, prostate-specific antigen level, and clinical stage. For PCPT, the analysis was performed using both original trial results and previously published adjusted analyses that attempted to account for artifacts related to the drugs' effect on prostate volume. RESULTS. For the PCPT trial, the estimated relative risk (RR) for prostate cancer mortality was 1.02 (95% confidence interval [95% CI], 0.85-1.23) using the original trial results and 0.87 (95% CI, 0.72-1.06) and 0.91 (95% CI, 0.76-1.09) based on the adjusted PCPT analyses. For the REDUCE trial, the RR for prostate cancer mortality was 0.93 (95% CI, 0.80-1.08). CONCLUSIONS. Projecting a mortality outcome of the PCPT and REDUCE trials as an approach to weighing benefits versus harms suggests at most a small increase in prostate cancer mortality in the treatment arms, and possibly a modest decrease. Cancer 2013. © 2012 American Cancer Society." @default.
• W1837385886 created "2016-06-24" @default.
• W1837385886 creator A5014213335 @default.
• W1837385886 creator A5015887484 @default.
• W1837385886 creator A5053628150 @default.
• W1837385886 creator A5055870934 @default.
• W1837385886 creator A5064396212 @default.
• W1837385886 creator A5072272174 @default.
• W1837385886 creator A5086081364 @default.
• W1837385886 date "2012-08-14" @default.
• W1837385886 modified "2023-09-25" @default.
• W1837385886 title "Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials" @default.
• W1837385886 cites W1973198827 @default.
• W1837385886 cites W1979522210 @default.
• W1837385886 cites W1981983512 @default.
• W1837385886 cites W2032356714 @default.
• W1837385886 cites W2067961971 @default.
• W1837385886 cites W2092596375 @default.
• W1837385886 cites W2096802466 @default.
• W1837385886 cites W2106329298 @default.
• W1837385886 cites W2108173967 @default.
• W1837385886 cites W2112467308 @default.
• W1837385886 cites W2113720631 @default.
• W1837385886 cites W2129302529 @default.
• W1837385886 cites W2132528779 @default.
• W1837385886 cites W2134793522 @default.
• W1837385886 cites W2139566281 @default.
• W1837385886 cites W2155530804 @default.
• W1837385886 cites W2159972811 @default.
• W1837385886 cites W3135529189 @default.
• W1837385886 cites W4362207783 @default.
• W1837385886 doi "https://doi.org/10.1002/cncr.27774" @default.
• W1837385886 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3502695" @default.
• W1837385886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22893105" @default.
• W1837385886 hasPublicationYear "2012" @default.
• W1837385886 type Work @default.
• W1837385886 sameAs 1837385886 @default.
• W1837385886 citedByCount "20" @default.
• W1837385886 countsByYear W18373858862013 @default.
• W1837385886 countsByYear W18373858862014 @default.
• W1837385886 countsByYear W18373858862015 @default.
• W1837385886 countsByYear W18373858862016 @default.
• W1837385886 countsByYear W18373858862017 @default.
• W1837385886 countsByYear W18373858862018 @default.
• W1837385886 countsByYear W18373858862019 @default.
• W1837385886 countsByYear W18373858862020 @default.
• W1837385886 countsByYear W18373858862022 @default.
• W1837385886 crossrefType "journal-article" @default.
• W1837385886 hasAuthorship W1837385886A5014213335 @default.
• W1837385886 hasAuthorship W1837385886A5015887484 @default.
• W1837385886 hasAuthorship W1837385886A5053628150 @default.
• W1837385886 hasAuthorship W1837385886A5055870934 @default.
• W1837385886 hasAuthorship W1837385886A5064396212 @default.
• W1837385886 hasAuthorship W1837385886A5072272174 @default.
• W1837385886 hasAuthorship W1837385886A5086081364 @default.
• W1837385886 hasBestOaLocation W18373858861 @default.
• W1837385886 hasConcept C120665830 @default.
• W1837385886 hasConcept C121332964 @default.
• W1837385886 hasConcept C121608353 @default.
• W1837385886 hasConcept C126322002 @default.
• W1837385886 hasConcept C143998085 @default.
• W1837385886 hasConcept C2775874879 @default.
• W1837385886 hasConcept C2776235491 @default.
• W1837385886 hasConcept C2778878792 @default.
• W1837385886 hasConcept C2780192828 @default.
• W1837385886 hasConcept C29456083 @default.
• W1837385886 hasConcept C44249647 @default.
• W1837385886 hasConcept C61511704 @default.
• W1837385886 hasConcept C71924100 @default.
• W1837385886 hasConcept C82789193 @default.
• W1837385886 hasConceptScore W1837385886C120665830 @default.
• W1837385886 hasConceptScore W1837385886C121332964 @default.
• W1837385886 hasConceptScore W1837385886C121608353 @default.
• W1837385886 hasConceptScore W1837385886C126322002 @default.
• W1837385886 hasConceptScore W1837385886C143998085 @default.
• W1837385886 hasConceptScore W1837385886C2775874879 @default.
• W1837385886 hasConceptScore W1837385886C2776235491 @default.
• W1837385886 hasConceptScore W1837385886C2778878792 @default.
• W1837385886 hasConceptScore W1837385886C2780192828 @default.
• W1837385886 hasConceptScore W1837385886C29456083 @default.
• W1837385886 hasConceptScore W1837385886C44249647 @default.
• W1837385886 hasConceptScore W1837385886C61511704 @default.
• W1837385886 hasConceptScore W1837385886C71924100 @default.
• W1837385886 hasConceptScore W1837385886C82789193 @default.
• W1837385886 hasIssue "3" @default.
• W1837385886 hasLocation W18373858861 @default.
• W1837385886 hasLocation W18373858862 @default.
• W1837385886 hasLocation W18373858863 @default.
• W1837385886 hasLocation W18373858864 @default.
• W1837385886 hasOpenAccess W1837385886 @default.
• W1837385886 hasPrimaryLocation W18373858861 @default.
• W1837385886 hasRelatedWork W1482749862 @default.
• W1837385886 hasRelatedWork W1976141923 @default.
• W1837385886 hasRelatedWork W1979522210 @default.
• W1837385886 hasRelatedWork W1979643613 @default.
• W1837385886 hasRelatedWork W2041830186 @default.
• W1837385886 hasRelatedWork W2085256729 @default.
• W1837385886 hasRelatedWork W2087131415 @default.

• next